Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the Patent Offices in Brazil and Israel have granted new patents for CM-101, Chemomab's first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive diseases involving fibrosis and inflammation. CM-101 i

Related Keywords

Israel ,Brazil ,Brazilian ,Israeli ,Wadi Mor ,Barbara Lindheim ,Strategic Communications ,European Union ,Chemomab Therapeutics Ltd ,That Recognize Additional ,Chief Executive Officer ,Chief Scientific Officer ,Orphan Drug ,Looking Statements ,Private Securities Litigation Reform ,Vice President ,Public Relations ,Um 101 ,Sc ,Monoclonal Antibody ,Patient Enrollment ,Hemomab ,